THEDERMA is building a diversified pipeline of AhR-targeted candidates across multiple therapeutic areas.
Based in Shanghai's Zhangjiang Science City, THEDERMA is focused on the discovery and development of therapeutics targeting the aryl hydrocarbon receptor (AhR). AhR is a ligand-activated transcription factor involved in immune regulation, barrier-tissue homeostasis, and inflammatory signaling. Its broad biological role supports the investigation of AhR modulation across a range of immune-mediated inflammatory diseases.
Based in Shanghai's Zhangjiang Science City, THEDERMA is focused on the discovery and development of therapeutics targeting the aryl hydrocarbon receptor (AhR). AhR is a ligand-activated transcription factor involved in immune regulation, barrier-tissue homeostasis, and inflammatory signaling. Its broad biological role supports the investigation of AhR modulation across a range of immune-mediated inflammatory diseases.
THEDERMA's R&D team includes scientists who invented and developed an approved AhR-targeted medicine. Building on this expertise, the company developed Zedman®, a non-steroidal topical AhR modulator for pediatric and adult patients. Clinical studies have demonstrated efficacy and a favorable safety profile, including in pediatric patients. The active ingredient has also received regulatory approval in the United States and other markets.
Beyond Zedman®, THEDERMA is advancing multiple AhR-targeted candidates across clinical and preclinical development. The company holds an executive vice-chair position in the China Dermatology Innovative Drug Alliance and received a 2024 Qipu Award nomination for pharmaceutical innovation. People’s Daily described the approval of Zedman® as “a microcosm of innovation in the biopharmaceutical industry.”
THEDERMA Shanghai Co., Ltd. was established and completed its angel financing, beginning its journey in AhR-targeted drug R&D.
The company’s first pipeline program received IND acceptance, laying the groundwork for subsequent clinical development.
THEDERMA completed its Series A financing and advanced multiple innovative programs into clinical development.
The company launched its first innovative medicine and continued to expand its global AhR pipeline.
Multiple first-in-class programs entered clinical development as THEDERMA strengthened its commercial capabilities.
THEDERMA continued to expand internationally and reinforce its leadership in AhR-targeted innovation.
Ph.D., Simon Fraser University, Canada
Postdoctoral Fellow, Yale University
25+ years of international pharmaceutical industry experience
Postdoctoral Fellow, Yale University, U.S.
Specialist in immunology and drug discovery
Postdoctoral Fellow, Yale University, U.S.
MBA, University of Chicago Booth School of Business
Ph.D., École Nationale Supérieure des Mines de Saint-Étienne, France
Former senior executive at a Fortune Global 500 healthcare company, with 20+ years of industry experience
Recipient of the Shanghai Magnolia Award
Ph.D., University of Washington, U.S.
20+ years of experience in pharmaceutical R&D, manufacturing and operations management
Ph.D., China Pharmaceutical University
20+ years of pharmaceutical industry experience
M.A., Columbia University
Extensive experience in pharmaceutical R&D management and corporate strategy
20+ years of executive leadership experience across leading healthcare companies
Ph.D., Shanghai Institute of Pharmaceutical Industry
10+ years of experience in pharmaceutical R&D and industrialization
Ph.D., McGill University, Canada
Ph.D. in Tumor Immunology, Faculty of Medicine, McGill University, Canada | Deep expertise in immune-mediated diseases and novel cancer target drug discovery
Ph.D., McGill University, Canada
Ph.D. in Experimental Medicine, Faculty of Medicine, McGill University, Canada | 10+ years in innovative drug development, with end-to-end expertise from bench to clinic